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OBJECTIVE— The excess risk of macrovascular disease and death associated with diabetes
seems higher in women than in men. The pathogenesis for this risk difference has not been fully
elucidated. We investigated whether female sex was associated with macrovascular disease and
death, independently of known risk factors related to type 2 diabetes, nephropathy, or retinop-
athy in normotensive patients with type 2 diabetes and microalbuminuria.
RESEARCH DESIGN AND METHODS— We conducted a prospective, prolonged
follow-up study of a subgroup of 67 diabetic patients (46 men and 21 women) without estab-
lished cardiovascular disease who participated in a larger clinical trial. Data were collected on
current and past health, medication use, blood pressure, renal function, and HbA1c during the
follow-up period of 4.7  0.8 (means  SE) years. The end point was a composite of death,
cardiovascular disease, cerebrovascular events, and peripheral artery disease.
RESULTS— Of the women, eight (38.1%) met the end point compared with six (13.4%) of
the men (P  0.02 for difference in event-free survival). The hazard ratio of women relative to
men was 3.19 (95% CI 1.11–9.21), which further increased after adjusting for age, systolic blood
pressure, BMI, smoking, total-to-HDL cholesterol ratio, urinary albumin excretion, and retinop-
athy.
CONCLUSIONS— In our study population of normotensive patients with type 2 diabetes
and microalbuminuria, female sex was associated with increased risk of fatal and nonfatal
cardiovascular disease, independent of the classical cardiovascular risk factors, the severity of
nephropathy or presence of retinopathy, or health care utilization.
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T ype 2 diabetes, with its rapidlygrowing prevalence, has become amajor public health problem (1). It
associates with an increased risk of coro-
nary heart disease, cerebrovascular dis-
ease, and peripheral vascular disease
(2,3). Strikingly, this excess risk for car-
diovascular disease seems relatively
higher for female than for male diabetic
patients (3–6). Type 2 diabetes substan-
tially contributes to the 500,000 women
dying annually of cardiovascular disease
in the U.S. It is unclear whether the dif-
ference in cardiovascular risk between the
sexes is caused by known cardiovascular
risk factors (like duration of diabetes and
systolic blood pressure) or by lower
health care utilization by women com-
pared with men (7,8).
In the present study, we extended the
prospective follow-up of normotensive
patients with type 2 diabetes and mi-
croalbuminuria who participated in a dou-
ble-blind, randomized, placebo-controlled
trial (9). The original study excluded pa-
tients with a history of cardiovascular dis-
ease, and the prolonged follow-up study
removed differences in health care utiliza-
tion among the participants.
In this study, we investigated whether
female sex was associated with cardiovas-
cular disease, cerebrovascular disease, pe-
ripheral artery disease, and death,
independently of the classical cardiovas-
cular risk factors related to type 2 diabe-
tes, nephropathy, and retinopathy.
RESEARCH DESIGN AND
METHODS— The present study is a
prolonged follow-up study of a subgroup
of patients (n 67) who participated in a
larger clinical trial. The study design,
methods, and results of this randomized,
double-blind, placebo-controlled multi-
center clinical trial have been previously
published (9). In the original trial, we in-
vestigated the effects of short-term treat-
ment with the angiotensin receptor
antagonist losartan in normotensive pa-
tients with type 2 diabetes and microalbu-
minuria. After the 20-week study period,
67 patients who had been recruited from
hospitals in the city of Rotterdam and sur-
rounding areas received standard medical
care. During follow-up, we collected the
data on current and past health, medica-
tion use, blood pressure, and laboratory
results of assessment of renal function
and HbA1c (A1C). The study was per-
formed according to the guidelines of
good clinical practice and was approved
by the institutional review board. All sub-
jects gave written informed consent be-
fore participation.
The eligibility criteria have been de-
scribed in detail (9). Briefly, patients with
type 2 diabetes, urinary albumin excre-
tion from 20 to 200 mg/l, and office mea-
surement of blood pressure 150/90
mmHg were randomized. Type 2 diabetes
was defined as diabetes diagnosed at age
30 years or controlled by diet or blood
glucose–lowering agents for at least 6
months. The current definition of normo-
tension is blood pressure 140/90
mmHg, with a blood pressure–lowering
target 130/80 mmHg in adults with di-
abetes (10,11). However, the protocol of
this study was designed in 1999, when nor-
motension was defined as blood pressure
160/90 mmHg during office measure-
ment. Our criteria resulted in a mean base-
line blood pressure of 135/81 mmHg,
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which can be regarded as normotensive at
present.
The main exclusion criteria included
a history of myocardial infarction or cere-
brovascular events, unstable angina pec-
toris, and heart failure. Patients with
electrocardiogram abnormalities, includ-
ing left ventricular hypertrophy, acute re-
nal failure, chronic glomerulonephritis,
polycystic kidney disease, serum creati-
nine level 150 mo/l, A1C 10%, or
concomitant use of antihypertensive
agents, steroids, or lithium, were ex-
cluded as well.
End points
The end point of the present study was a
composite of death, acute myocardial in-
farction, unstable angina pectoris, coro-
nary interventions, heart failure, cerebral
ischemic stroke or transient ischemic at-
tack, and peripheral artery disease (pe-
ripheral arterial bypass graft, peripheral
percutaneous transluminal angioplasty or
other percutaneous invasive intervention,
or intermittent claudication defined as
classical symptoms in combination with
at least one unequivocal result of one of
the following: ankle/arm index0.9 or a
stenosis [50%] on an angiogram or du-
plex scan). Patients with a history of car-
diovascular disease were excluded from
the original trial, restricting our observa-
tions to incident events.
Statistical analyses
Continuous variables are presented as
means SE and discrete variables as fre-
quencies and percentages. The indepen-
dent Student’s t test was used for
comparisons between men and women.
Cumulative event-free survival was ana-
lyzed with the Kaplan-Meier method and
the log-rank test, as well as with Cox re-
gression. The 95% CI of the hazard ratio
was calculated as the exponent of the re-
gression coefficient and its SE.
As we questioned whether female sex
was an independent risk factor for macro-
vascular outcome in our study popula-
tion, we used clinical variables, important
with regard to macrovascular complica-
tions in type 2 diabetes, which were sig-
nificantly different between the sexes at
baseline in our multiple Cox regression
models. We also adjusted for other classi-
cal cardiovascular risk factors. Two Cox
regression models were performed to in-
vestigate whether the level of baseline al-
buminuria or the presence of retinopathy,
respectively, could explain for possible
sex differences, thereby being able to
serve as risk indicators of those patients
with the highest cardiovascular risk. Sta-
tistical significance was assessed at the 5%
level of probability. We used SPSS 12.0.1
for Windows (SPSS, Chicago, IL) for all
analyses.
RESULTS— Table 1 shows character-
istics according to sex at baseline and after
a mean follow-up of 4.7  0.8 years.
Women had a higher baseline systolic
blood pressure and BMI compared with
the men. Age, duration of diabetes, A1C
levels, diastolic blood pressure, severity of
urinary albumin excretion, frequency of
current smoking, and frequency of reti-
nopathy did not differ between men and
women. At baseline, 46 (68.7%) patients
were treated with an insulin-based re-
gime, the remaining 21 (31.3%) with oral
glucose-lowering agents only. As a result
of the inclusion criteria, no antihyper-
tensive treatment was used at baseline. At
the end of the follow-up period, 93% of
the patients used antihypertensive treat-
ment, of which 98% consisted of blockers
of the renin-angiotensin aldosterone sys-
tem, in minority in combination with any
of the other classes of antihypertensive
medication.
During 85.9 person-years, eight
(38.1%) women had a cardiovascular
event (cardiovascular disease: three, cere-
brovascular disease: two, and peripheral
Table 1—Characteristics of men and women at baseline and after a 5-year follow-up
Men Women P value
n 46 21
Baseline
Age (years) 56.0  1.8 54.0  2.8 0.5
Duration of diabetes (years) 14.3  1.5 15.7  1.7 0.5
A1C (%) 8.1  1.3 8.0  1.0 0.7
BMI (kg/m2) 27.7  0.7 31.6  1.2 0.008
Systolic blood pressure (mmHg) 133.9  1.7 139.2  1.9 0.04
Diastolic blood pressure (mmHg) 79.4  1.1 81.6  1.6 0.3
Total-to-HDL cholesterol ratio 5.38  0.3 4.6  0.3 0.06
Current smoking (%) 30 38 0.6
Serum creatinine (mol/l) 84.8  2.3 74.0  4.7 0.05
Urinary albumin excretion (mg/l) 70.4  6.1 81.8  11.3 0.3
Retinopathy (%) 27 48 0.1
5-year follow-up
A1C (%) 8.6  1.4 8.3  1.0 0.4
Systolic blood pressure (mmHg) 139.5  2.6 140.3  3.5 0.9
Diastolic blood pressure (mmHg) 79.9  6.5 77.2  7.8 0.2
Serum creatinine (mol/l) 89.0  3.8 81.3  4.5 0.2
Urinary albumin excretion (mg/l) 133.7  40.1 124.4  34.2 0.9
Antihypertensive medication (%) 89 100 0.03
Aspirin (%) 23.3 28.6 0.7
Statin use (%) 55 48 0.6
Data are means  SE.
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artery disease: three, and no deaths were
reported), and during 198.5 person-
years, six (13.4%) men also met the com-
posite end point (cerebrovascular disease:
two; peripheral artery disease: two; death:
two [one because of cerebral hemorrhage
and one because of cardiac arrest]). One
man who first developed peripheral ar-
tery disease also developed cerebrovascu-
lar disease as well as cardiovascular
disease, and one man who first developed
cerebrovascular disease also developed
peripheral artery disease. The time to the
first event in those two men counted for
the event-free survival time. The Kaplan-
Meier showed a significant difference in
event-free survival between women and
men (P  0.02) (Fig. 1).
Table 2 shows that women had 3.19
(95% CI 1.11–9.21) times higher risk of
cardiovascular disease risk in univariate
analysis relative to men. In this study, we
questioned whether female sex was an in-
dependent risk factor for macrovascular
outcome in normotensive patients with
type 2 diabetes and microalbuminuria. As
demonstrated in Table 1, BMI and systolic
blood pressure were significantly differ-
ent between both men and women. In our
multiple Cox regression models, we put
in these variables to exclude that the ob-
served increased risk in women is due to
higher baseline systolic blood pressure or
BMI in women. Furthermore, we adjusted
for other classical cardiovascular risk fac-
tors, such as age, smoking, and total-to-
HDL cholesterol ratio.
We have made two multiple Cox re-
gression models to analyze the effect of
nephropathy and retinopathy: models 1
and 2, respectively, in Table 2. In model
1, after adjustment for age, systolic blood
pressure, BMI, total-to-HDL cholesterol
ratio, smoking, and urinary albumin ex-
cretion, the hazard ratio of the women
relative to men increased to 6.40 (95% CI
1.24–32.93). In model 2, the point esti-
mate of the cardiovascular risk of women
relative to men increased to 8.23 (1.81–
37.62).
CONCLUSIONS— In the present
prospective follow-up study, we observed
that female sex was an independent and
important cardiovascular risk factor in
normotensive patients with type 2 diabe-
tes and microalbuminuria. Adjustment
for the classical cardiovascular risk fac-
tors, such as age, systolic blood pressure,
BMI, smoking, total-to-HDL cholesterol
ratio, and severity of albuminuria or pres-
ence of retinopathy, further increased the
excess risk of women. Hence, we could
not have identified the women at baseline
who had an event afterward. Women en-
tered the present study with a significantly
higher mean systolic blood pressure than
men, although without differences between
the sexes in signs of organ damage. During
follow-up, significantly more women were
treated with antihypertensive drugs, result-
ing in similar systolic blood pressure in both
sexes. This showed that the risk difference
between the sexes was also not the result of
differences in access to health care.
Previous studies (12) have shown that
women with diabetes lose their usual rel-
ative protection (compared with men)
against cardiovascular disease. Estimates
of cardiovascular mortality in diabetic
women range from two- to fivefold the
rate in nondiabetic women, whereas in
diabetic men, estimates vary from one- to
threefold the rate in nondiabetic men
(13). Data about the reasons for this ex-
Figure 1—Kaplan-Meier estimates of event-free survival in women andmenwith type 2 diabetes.
Women had significantly shorter event-free survival comparedwithmen (log-rank test;P 0.02).
Table 2—Hazard ratios for composite cardiovascular end point of women relative to men
Variables Hazard ratio (95% CI) P value
Univariate
Women relative to men 3.19 (1.11–9.21) 0.03
Multiple Cox regression: model 1
Women relative to men (adjusted for age,
systolic blood pressure, BMI, total-to-
HDL cholesterol ratio, current smoking,
and urinary albumin excretion)
6.40 (1.24–32.93) 0.02
Multiple Cox regression: model 2
Women relative to men (adjusted for age,
systolic blood pressure, BMI, total-to-
HDL cholesterol ratio, current smoking,
and retinopathy)
8.23 (1.81–37.62) 0.009
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cess risk of cardiovascular disease in dia-
betic women are conflicting. In a number of
studies (7,8,14), differences in the distribu-
tions of other major risk factors explained
the sex difference in cardiovascular disease
risk to a great extent. A recently published
meta-analysis established an estimate of
the odds ratio for fatal and nonfatal car-
diovascular disease due to diabetes in
both women and men. The authors con-
cluded that after adjusting for the well-
established, modifiable cardiac risk
factors, the difference in risk between
women and men is modest and not statis-
tically significant (8). To our knowledge,
our study is the first prospective fol-
low-up study that investigated normoten-
sive type 2 diabetic patients who had
microalbuminuria, without previously
established cardiovascular diseases.
The women of our study population
had a higher baseline systolic blood pres-
sure as well as a higher BMI compared
with the men. However, adjustment for
these differences did not change the car-
diovascular risk between the sexes. Levels
of blood pressure and A1C did not reach
the current treatment goals during fol-
low-up but were similar in both men and
women and did not change the cardiovas-
cular risk between the sexes in multivari-
ate Cox analysis. Moreover, our results
during follow-up indicate that women and
men were according to the same protocol,
achieving identical treatment targets.
Microalbuminuria has been consid-
ered as an indicator of endothelial dys-
function, as well as the first clinical sign of
diabetic nephropathy (15,16). It is asso-
ciated with cardiovascular morbidity and
all-cause mortality in both type 1 and type
2 diabetes as well as in nondiabetic indi-
viduals (17,18). In the present study, the
level of urinary albumin excretion did not
explain the sex difference observed in our
study population. Moreover, adjustment
for the presence of retinopathy at base-
line, an important microvascular compli-
cation of type 2 diabetes and a sign of
arterial atherosclerosis, also did not ex-
plain the high risk among women with
type 2 diabetes.
The strength of the present study lies
in its prospective design and the absence
of prevalent cardiovascular disease at
baseline, in spite of the presence of mi-
croalbuminuria. Moreover, diabetes was
equally complicated with retinopathy and
nephropathy in women and men. An im-
portant limitation of our study is the small
sample size. Nonetheless, in concordance
with previous studies, we observed statis-
tically significant differences between
women and men with regards to cardio-
vascular risk, which further increased af-
ter multivariate regression anlyses.
Furthermore, as our patients did not meet
the treatment targets, it would be interest-
ing to investigate whether the event rates
and sex differences still exist when the
current, more aggressive treatment goals
for blood pressure lowering as well as
A1C are achieved.
In summary, we conclude that female
sex is an independent risk factor for ma-
crovascular disease and death in our study
population of normotensive patients with
type 2 diabetes and microalbuminuria. This
excess risk of women relative to men could
not be explained by differences in other
classical cardiovascular risk factors, the
severity of nephropathy or presence of
retinopathy, or health care utilization. In
contrast to recent studies, our observa-
tions suggest that the cardiovascular risk
of women with type 2 diabetes can be eas-
ily underestimated when additional risk
factors are made mandatory. Further re-
search is needed to fully elucidate the
pathogenesis of this excessive risk in
women with type 2 diabetes because, at
this point, we did not find risk indicators
that discriminate between women with
high and low risk of cardiovascular disease.
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